entertainment -WSS

entertainment

author：comprehensive 2025-09-30 23:39:22 - browse：8

Tome cofounders Jonathan Gootenberg, left, and Omar Abudayyeh, a scientific team that's trying to reinvent gene editing for a new era of biotech innovation. — Suzanne Kreiter/Globe staff

WATERTOWN — Their brainstorming began in an MIT class in 2010 when the eager undergrads shot each other emails about how to solve a bioengineering equation. It has continued for 14 years over sushi dinners, between Marvel movies, and during rowing-machine workouts.

Together, Omar Abudayyeh, 33, and Jonathan Gootenberg, 32, have probed the mysteries of genomic editing and COVID detection. They co-published 10 scientific papers, helped launch two medical-diagnostic companies, and cofounded a Watertown startup, Tome Biosciences, that reengineers genes and cells to cure diseases. They also run the Abudayyeh-Gootenberg Lab at Harvard.

Gootenberg and Abudayyeh are an unusual pair, two scientists — a Jewish American and a Palestinian American — who prefer working together in a field that often draws solitary researchers and rewards individual achievement.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： Profiling embryos to choose those with higher IQs is almost a reality

leisure time

WSS

Arena BioWorks launches in Cambridge to speed drug discovery

Medicare Advantage overpayments discussion gets experts fired up

Study suggests new cause of Down syndrome: cells linked to aging

STAT Virtual Event: The State of Biosimilars: What to Watch

Stories you might have missed in 2023: health, science, medicine

Male doctors called my cancer incurable. A female doctor showed it wasn't

explore

entertainment

entertainment

After affirmative action ruling, medical educators look to 'holistic review'

JPM 2024 Review: Hope for the XBI, deals from J&J, Merck, GSK

Malaria cases in Florida and Texas: Here’s what you need to know

Detailed data confirm benefits, risks of Eli Lilly's Alzheimer's drug

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

At Orexo, a ‘turning point’ for everything but digital health

Tori Bowie and the unacceptable rates of Black maternal death

Key House panel plots a new health care package

Medical leaders decry Supreme Court decision on affirmative action

JPM 2024: Biotech’s most prolific dealmaker sees a rosy 2024

leisure time

Biden tests positive for Covid

Stories you might have missed in 2023: health, science, medicine

Listen: Wegovy in the brain & pivotal Alzheimer's data

JPM pitch from hospitals? Revenue streams outside of patient care

In early work, researchers turn to CRISPR to treat Alzheimer's

Does Paxlovid work in people vaccinated against Covid

hotspot

leisure time

knowledge

focus